|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...99100101102103104105106107108109...39323933» |
- | Yescarta (axicabtagene ciloleucel) / Gilead
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain. (Pubmed Central) - Jul 13, 2024
Axi-cel is a potentially cost-effective alternative to HDT+ASCT for the treatment of R/R DLBCL in Spain.
- | BMS-202 / BMS
Journal: Computational Approach for the Development of pH-Selective PD-1/PD-L1 Signaling Pathway Inhibition in Fight with Cancer. (Pubmed Central) - Jul 13, 2024
A detailed 1000 ns molecular dynamics simulation confirmed the stability of the inhibitor-PD-L1 complex under acidic conditions. This research highlights the potential of using in silico techniques to discover novel pH-selective inhibitors, which, after experimental validation, may enhance the precision and reduce the toxicity of immunotherapies, offering a transformative approach to cancer treatment.
- | Verzenio (abemaciclib) / Eli Lilly
Preclinical, Journal: HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. (Pubmed Central) - Jul 13, 2024
However, abemaciclib-treated hormone receptor-positive breast cancer patients with tumor-associated mdm2 gene copy gains or pronounced HER4 expression showed a reduced event-free survival. Evidently, the presence of HER4 affects the efficacy of tamoxifen and abemaciclib treatment in different estrogen receptor-positive breast cancer cells, even to different extents, and is associated with unfavorable outcomes in abemaciclib-treated patients.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: TNFSF9 Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab. (Pubmed Central) - Jul 13, 2024
This suggests that not only PD-1 but also CTLA-4 inhibition may have suppressed Treg activation and improved the therapeutic effect in the TNFSF9 high-expression tumors. Therefore, TNFSF9 may predict the therapeutic efficacy of NIVO + IPI for mRCC and allow more appropriate patient selection.
- | Verzenio (abemaciclib) / Eli Lilly
Journal: Synergistic Enhancement of Antitumor Effects by Combining Abemaciclib with Desipramine. (Pubmed Central) - Jul 13, 2024
The combination treatment significantly reduced tumor size compared with control or single treatment without causing apparent toxicity to normal tissues. Although additional in vivo studies are necessary, this study suggests that the combination therapy of abemaciclib and desipramine may represent a novel therapeutic approach for treating solid tumors.
- || Tevimbra (tislelizumab-jsgr) / BeiGene, Votrient (pazopanib) / Novartis, BeiGene, Darzalex (daratumumab) / J&J
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Long-Term Remission with Novel Combined Immune-Targeted Treatment for Histiocytic Sarcoma Accompanied by Follicular Lymphoma: Case Report and Literature Review. (Pubmed Central) - Jul 13, 2024
Duration of remission and overall survival reached 22 and 32 months, respectively. Our case indicated that immuno-targeted treatment coupled with chemotherapy and radiotherapy might constitute a potential therapeutic option for HS.
- || Elzonris (tagraxofusp-erzs) / Menarini
Review, Journal: Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View. (Pubmed Central) - Jul 13, 2024
Treatment options range from conventional chemotherapy to the recently approved biologic agent tagraxofusp and stem cell transplantation. Therefore, a multidisciplinary approach with coordination among dermatologists, pathologists, and hematologists is ultimately imperative to reach the correct diagnosis and management of BPDCN.
- || Rituxan (rituximab) / Roche
Review, Journal: A Comprehensive Outlook on Pulmonary Alveolar Proteinosis-A Review. (Pubmed Central) - Jul 13, 2024
The gold standard for PAP treatment is whole-lung lavage. This review presents a summary of the most recent findings concerning pulmonary alveolar proteinosis, pointing out specific features that require further investigation.
- || Herceptin (trastuzumab) / Roche, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Review, Journal: Antibody-Drug Conjugates-Evolution and Perspectives. (Pubmed Central) - Jul 13, 2024
Major aspects such as development strategies are first discussed, advantages and disadvantages, safety and efficacy, offering a retrospective insight on the subject. The second part of the review is prospective, focusing on various plans to overcome the previously identified difficulties.
- | sunitinib / Generic mfg.
Biomarker, Journal: Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients. (Pubmed Central) - Jul 13, 2024
Using in situ hybridisation (ISH) to detect miR-155 we observed higher tumoural cell expression in non-responders, and non-tumoural cell expression with increased histological grade. In summary, our preliminary analysis using integrated miRNA-target gene analyses identified several novel biomarkers in ccRCC patients that surely warrant further investigation.
- | Verzenio (abemaciclib) / Eli Lilly
Journal: Development of a Radiolabeled Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitor for Brain and Cancer PET Imaging. (Pubmed Central) - Jul 13, 2024
NT431, a newly synthesized 4-fluorobenzyl-abemaciclib, exhibited high potency to CDK4/6 and against four cancer cell lines with IC50 similar to that of the parent abemaciclib...However, despite the modest BBB penetration, [18F]NT431 represents an important step towards the development and evaluation of a new generation of CDK4/6 inhibitors with superior BBB penetration for the treatment and visualization of CDK4/6 positive tumors in the CNS. Also, [18F]NT431 may have potential application in peripheral tumors such as breast cancer and other CDK4/6 positive tumors.
- || Review, Journal, Combination therapy: Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies. (Pubmed Central) - Jul 13, 2024
This review addresses the clinical trials of immunotherapies for early-, intermediate-, and advanced-stage HCC. Additionally, it highlights how combination therapy can significantly enhance overall survival, progression-free survival, and objective response rate in advanced-stage HCC, where treatment options are limited.
- | Mulpleta (lusutrombopag) / Shionogi
Journal, Real-world evidence, Real-world: Final Results from the First European Real-World Experience on Lusutrombopag Treatment in Cirrhotic Patients with Severe Thrombocytopenia: Insights from the REAl-World Lusutrombopag Treatment in ITalY Study. (Pubmed Central) - Jul 13, 2024
In this first European real-world series, lusutrombopag demonstrated efficacy and safety consistent with the results of registrational studies. According to our results, patients with baseline platelet counts ?29,000/?L are unlikely to respond to the drug.
- | Rituxan (rituximab) / Roche
Journal: Unraveling the Clinical Features and Outcomes of IgG4-Related Ophthalmic Disease. (Pubmed Central) - Jul 13, 2024
The group including hydroxychloroquine (HCQ), which comprised 5 out of 33 patients (15.2%), showed no recurrence at 1 year. The combination therapy of GCS and SSA for IgG4-ROD can be considered an effective treatment approach and HCQ could be considered as a potential adjunctive therapy for IgG4-ROD.
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Review, Journal: Survival and Treatment Modalities in Primary Vaginal Melanoma-Case Report and a Narrative Review. (Pubmed Central) - Jul 13, 2024
The combination of the wide local excision of the primary lesion followed by adjuvant therapies results in the best outcomes in the treatment of PVM. Future clinical studies are warranted to provide new evidence for the treatment outcomes of nonsurgical, metastatic PVM and the adjuvant treatment of PVM.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. (Pubmed Central) - Jul 13, 2024
Prior immunotherapy included a single-agent treatment in 83% of cases, with pembrolizumab use being prevalent, and a median N/L ratio of four prior to chemotherapy...A median of 4 (range 1-16) cycles of chemotherapy were administered; platinum doublets (primarily carboplatin) were delivered in only 31% of cases, vinorelbine accounted for 25%, taxanes for 25%, and gemcitabine for 8%...Following immunotherapy advancement, chemotherapy demonstrated a moderate level of therapeutic effectiveness; no adverse concerns were noted. The effectiveness of chemotherapy following immunotherapy was not predicted by the baseline N/L ratio.
- | Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. (Pubmed Central) - Jul 13, 2024
Now, two studies in the adjuvant setting - MonarchE (2 years of abemaciclib) and NATALEE (3 years of ribociclib) - report positive invasive disease-free survival. The NATALEE strategy, in particular, could affect up to 35
- Tevimbra (tislelizumab-jsgr) / BeiGene
Neoadjuvant Chemotherapy plus Tislelizumab Followed by Adjuvant Tislelizumab for Locoregionally Advanced Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2941;
- Keytruda (pembrolizumab) / Merck (MSD)
Time and Financial Toxicity Implications during Consideration of Pembrolizumab Infusion Frequency (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2914;
- Opdivo (nivolumab) / BMS
Effect of Time-of-Day Nivolumab and Stereotactic Body Radiotherapy in Metastatic Head and Neck Squamous Cell Carcinoma: A Secondary Analysis of a Prospective Randomized Trial (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2875;
- Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Safety and Activity Profile of Fianlimab (Anti-LAG-3) in Combination With Cemiplimab (Anti-PD-1) and Cemiplimab Monotherapy in Recurrent and/or Metastatic HNSCC (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2835;
- Keytruda (pembrolizumab) / Merck (MSD)
Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC) (Room 146) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2692;
- Rituxan (rituximab) / Roche
Ultra-Low-Dose Adaptive Radiotherapy and Single-Agent Rituximab for Indolent Non-Hodgkin Lymphomas: Where Less is More in Combined Modality Therapy (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2576;
- Tecartus (brexucabtagene autoleucel) / Gilead
Bridging Radiotherapy prior to Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2547;
- Inlyta (axitinib) / Pfizer, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Mid-Term Analysis of the Combination Therapy of Axitinib, Toripalimab, and Stereotactic Ablative Body Radiotherapy (SABR) in the Treatment of Recurrent Metastatic Renal Cell Carcinoma (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2289;
- Inlyta (axitinib) / Pfizer, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
A Phase Il Clinical Study of Axitinib and Toripalimab Combined with Stereotactic Radiation (SBRT) for Metastatic Renal Cell Carcinoma (mRCC) after Oligoprogression from First-Line Anti-Angiogenic Ther (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2285;
- Keytruda (pembrolizumab) / Merck (MSD)
Dosimetric Predictors of Acute Hematological Toxicity during nCRT with or without Pembrolizumab for Esophageal Squamous Cell Carcinoma (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2133;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2119;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Preoperative Short-Course Radiotherapy Combined with Chemotherapy and Tislelizumab for Locally Advanced Middle-Low Rectal Cancer: A Randomized Phase I/II Clinical Study (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2106;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Tislelizumab plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients after Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Stu (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2103;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Toripalimab plus Chemotherapy and Radiotherapy for Treatment-Naive, Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Trial (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2102;
- Tyvyt (sintilimab) / Eli Lilly
Phase II Study of Sintilimab Combined with Chemotherapy and Sequential Radiotherapy in First-Line Treatment of Oligometastatic Esophageal Cancer (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2101;
- Avastin (bevacizumab) / Roche, Imfinzi (durvalumab) / AstraZeneca
EMERALD-Y90: A Phase 2 Study to Evaluate Transarterial Radioembolization Followed by Durvalumab and Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma Eligible for Embolization (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2085;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Efficacy and Safety of Toripalimab Combined with Radiotherapy and S-1 Followed by Adjuvant Toripalimab Maintenance Therapy for Older Patients with Esophageal Cancer (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2079;
- Keytruda (pembrolizumab) / Merck (MSD)
First Exploration of the Characterization and Dosimetric Predictors for Absolute Lymphocyte Count Changes during nCRT with or without Pembrolizumab for Esophageal Squamous Cell Carcinoma: An Analysis (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2073;
- Tyvyt (sintilimab) / Eli Lilly
Sintilimab Combined with Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Multicenter, Phase 2 Trial (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2044;
- Keytruda (pembrolizumab) / Merck (MSD)
The Addition of Pembrolizumab to Neoadjuvant Chemoradiotherapy did not Increase the Risk of Developing Postoperative Anastomotic Leakage for ESCC: An Analysis from a Prospective Cohort (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2034;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Neoadjuvant Tislelizumab Combined with Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Study and Exploration of Immunologic Features (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_2012;
- Keytruda (pembrolizumab) / Merck (MSD)
Pattern of Primary Tumor Residual and Lymph Node Spread in Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy with or without Pembrolizumab (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1999;
- Avastin (bevacizumab) / Roche, Imfinzi (durvalumab) / AstraZeneca
mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1982;
- Bavencio (avelumab) / EMD Serono
Combining Avelumab with Platinum/5-Fluorouracil and Radical Hypofractionated Radiotherapy for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Prospective Trial (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1973;
- Tyvyt (sintilimab) / Eli Lilly
A Phase II Clinical Trial of Sintilimab Combined with Lower Dose Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1971;
- Tevimbra (tislelizumab-jsgr) / BeiGene, Fruzaqla (fruquintinib) / Takeda
Stereotactic Ablative Radiotherapy Combined with Fruquintinib and Tislelizumab in Metastatic Colorectal Cancer: Updated Findings from a Single-Arm, Prospective Phase II Trial (RIFLE) (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1969;
- Opdivo (nivolumab) / BMS, BMS-986156 / BMS, Yervoy (ipilimumab) / BMS
Final Report of a Phase I/II Study of BMS-986156 (Glucocorticoid-Induced TNFR-Related Gene [GITR] Agonist) with Ipilimumab or Nivolumab with/without Stereotactic Ablative Radiotherapy in Patients with (Room 140) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1854;
- Ibrance (palbociclib) / Pfizer
ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer (Room 140) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1853;
- Opdivo (nivolumab) / BMS
Exploratory Analysis of Plasma Protein Abundance Kinetics from I-SABR, A Randomized Phase II Trial of Stereotactic Ablative Radiotherapy with or without Nivolumab in Stage I-IIA or Recurrent Non-Small (Room 147) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1839;
- Imfinzi (durvalumab) / AstraZeneca, Ilaris (canakinumab) / Novartis
Exploratory Analysis of ctDNA and Imaging Response in the Phase I/II CHORUS Study of Canakinumab with Chemoradiation and Durvalumab Consolidation for Stage III NSCLC (Room 207) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1597;
- Verzenio (abemaciclib) / Eli Lilly
Safety and Feasibility of Concurrent Abemaciclib and Postoperative Radiotherapy for Breast Cancer: A Real-World Analysis (Hall C) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1543;
- AiRuiKa (camrelizumab) / HLB Bio Group
Pathologic Response Prediction Value of 18f-Fapi PET/CT in ESCC Treated with Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial (Room 145) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1434;
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer (Room 207) - Jul 13, 2024 - Abstract #ASTRO2024ASTRO_1419;